Optimizing Outcomes for Patients with Urothelial Carcinoma: Recent Clinical Updates

Release Date: September 30, 2020 

Expiration Date: September 29, 2021

This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, Astellas, and Seattle Genetics, Inc.

Target audience

The target audience for this initiative includes medical oncologists, urologic oncologists, urologists, advanced practice providers (nurse practitioners, physician assistants, oncology pharmacists), oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with urothelial carcinoma.


In a recent survey of community cancer care professionals conducted by the Association of Community Cancer Centers, bladder was reported to be one of the most commonly diagnosed cancers after breast, lung, prostate, and colorectal. For many community oncologists, it is hard to stay abreast of clinical updates and changing treatment recommendations across all tumor types. This initiative will summarize recent clinical data for immunotherapies and emerging targeted therapies used to treat advanced and metastatic urothelial carcinoma. Strategies for identification and management of treatment-related adverse events, as well as effective solutions for improving multidisciplinary care coordination, will also be covered.  


At the end of this educational initiative, for patients with locally advanced or metastatic urothelial carcinoma, participants should be able to …

  • Review available evidence for the use of checkpoint inhibitors and novel agents, including antibody drug conjugates and fibroblast growth factor receptor (FGFR) inhibitors
  • Explore strategies for identification and management of immune-related and FGFR inhibitor-associated adverse events
  • Outline effective solutions for improving coordination and communication within the multidisciplinary cancer care team to improve patient outcomes

Your Faculty

Pedro C. Barata, MD, MSc  
Assistant Professor, Deming Department of Medicine
Division of Hematology/Oncology, Genitourinary Cancers
Tulane University 

Accreditation Statement

Jointly Accredited Provider LogoIn support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Credit Designation for Physicians AXIS Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nursing AXIS Medical Education designates this continuing nursing education activity for 0.75 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

AXIS Contact Information For information about the accreditation of this program please contact AXIS at info@axismeded.org.

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of  Planner / Manager / Reviewer / AdvisorReported Financial Relationship
Pedro Barata, MD, MSc                                                                                          Consultant (Institution): Astellas; Bayer Pharmaceuticals Corp; Bristol Myers Squibb; Caris; Clovis Oncology; Eisai; EMD Serono; Dendreon; Janssen Pharmaceuticals, Inc. - a pharmaceutical company of Johnson & Johnson; and Pfizer, Inc.  

Contracted Research
: AstraZeneca and BlueEarth Diagnostics

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Planner / Manager / Reviewer / AdvisorReported Financial Relationship
Latha Shivakumar, PhD                              Nothing to disclose 
Mary Stanley, PMPNothing to disclose 
Leigh M. Boehmer, PharmD, BCOPNothing to disclose 
Marilyn Haas, PhD, RN, CNS, ANP-BCNothing to disclose 
Dee Morgillo, MEd.,CHCPNothing to disclose 
Robert Mocharnuk MD
Common Stock: Merck


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

This webinar is open to the public. You do not need to be an ACCC member to view this webinar, but you will need to create an account in order to register.  

 If You DO NOT Have an ACCC Account: 

  • To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page. 
  • ACCC and State Society Members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page.  
  • Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page.  
  • Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link. 
  • The green box in the upper right corner of this page will indicate “You are registered!” for this course! 

If You Have an ACCC Account: 

  • Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button. 
  • You will be automatically redirected back to webinar page, and the green box in the upper right corner will say that “You are registered!” for this course! 

PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!  

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer Users may experience difficulties accessing the webinar. 

Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this webinar. For assistance with registration or if you do not receive an email, please contact registration@accc-cancer.org.

Pedro C. Barata, MD, MSc

Assistant Professor of Medicine Hematology & Medical Oncology, Tulane University

Dr. Pedro Barata earned his medical degree from the New University of Lisbon in 2009 and completed his medical oncology training in 2016. Subsequently, he was invited to join the genitourinary group at Taussig Cancer Center, where he worked as a clinical fellow in genitourinary malignancies. Dr. Barata then moved to Tulane University to continue his clinical and research work in the GU field. Dr. Barata successfully expanded the genitourinary program offered at Tulane Cancer Center and he currently leads the kidney and bladder cancer program at Tulane University with a focus on clinical trials.  

 Dr. Barata has authored or co-authored more than 60 research publications in high-quality journals, such as Cancer, Annals of Oncology, and CA: Cancer journal Clinicians, with more than 700 scientific citations. He has presented multiple abstracts at important national and international meetings and has won multiple prestigious awards, including the Scholar-in-Training Award, AACR-NCI-EORTC Triple Meeting (2017) and the Annual Accelerating Anticancer Agent Development and Validation (AAADV) Program Scholarship (2018). He serves as a reviewer for prestigious peer-reviewed journals, such as JAMA Oncology, ASCO and Journal Global Oncology. 


4 Questions
Course Content
Recorded 09/22/2020
Recorded 09/22/2020 After viewing the lecture, please complete the post assessment and the course evaluation to receive CE credit.
Post-activity Assessment
4 Questions  |  3 attempts  |  3/4 points to pass
4 Questions  |  3 attempts  |  3/4 points to pass Please take a moment to complete this post-assessment. This assessment is graded. Passing score is required to obtain CE credit.
Course Evaluation
11 Questions
11 Questions This evaluation must be completed to receive credit for this course. Estimated time to complete is 5 minutes.
CME/CNE/Certificate of Participation
Up to 0.75 medical credits available  |  Certificate available
Up to 0.75 medical credits available  |  Certificate available Claim credits in .25 increments. Please note: If you have completed a course prior to May 2020 and need a copy of your CME or CNE certificate, please email rburtnick@accc-cancer.org and include your full name, credentials, course name, and email address.